AzTrials
AzTrials

Esophageal DiseasesNCT05004155

Twenty Four Hour Ambulatory pH & Impedance Testing: Normative Data for Indian Population

An observational study of Esophageal Diseases and Esophagitis, run by Asian Institute of Gastroenterology, India at 1 site in India.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

GERD is common in Indian population and the normative data which is used to diagnose \& manage GERD and its complications are based on western data which is not validated in the Indian population. Read more about this study

Who is it for?
Ages 18 years and olderHealthy volunteers can take part
Conditions the study is for
Esophageal Diseases, Esophagitis, Reflux Disease
What is being tested?
24 hour pH & impedance monitoring
How many people
50 participants
Where
1 siteIndia
Study dates
1 Jun 2021to 31 Dec 2022
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Study population: The study will enroll only healthy asymtomatic subjects, so that normative data can be generated.

Who may be able to join

  • Healthy individual > 18 years of age
  • Not on any acid lowering drug from at least 7 days.

Who cannot join

  • Thoracic or digestive foregut surgery,
  • Alcohol consumption >40 g/day,
  • Use of medications that alter intragastric acidity or oesophageal motility
  • History of diabetes mellitus,
  • Neurological disorders
  • Chronic gastrointestinal disease
  • Any subject with upper GI symptoms like pain, burning, belching, bloating, dysphagia \& aerophagia

Trial locations and contacts

1 site in 1 country.

Anirrudha P Singh, MBBS, MD, DM contact

9004093248 ext. 91

draniruddhapratapsingh@gmail.com

Neeraj Singla, MBBS, MD, DM contact

7888619216 ext. 91

dr.neerajsingla@gmail.com

India1 site, 1 recruiting
  • AIG Hospitals

    Hyderabad, Telangana, 500032

    Aniruddha P Singh, MBBS,MD,DM, 09004093248, draniruddhapratapsingh@gmail.com

    Neeraj Singla, MBBS,MD,DM, 07888619216, dr.neerajsingla@gmail.com

    Recruiting

Other trials in India

About this study

GERD is common in Indian population and the normative data which is used to diagnose \& manage GERD and its complications are based on western data which is not validated in the Indian population. Although normative data is available for commonly used twenty-four impedance-pH parameters, their global application has limitations, stemming from use of small healthy volunteer cohorts from few countries for normative data. At present, there is no normative data for twenty-four hours impedance-pH monitoring in Indian population. The aim of this study is to obtain a new set of normal values specific for the Indian population.

Read the detailed description
  1. INTRODUCTION Ambulatory impedance-pH monitoring is well established in the investigation of oesophageal symptoms suspicious of gastro-oesophageal reflux disease (GERD), and may be of particular value where symptoms persist or do not improve with empiric GERD treatment trials or GERD management, or where the diagnosis of GERD is inconclusive. Although normal values are available for commonly used impedance-pH parameters, their global application has limitations, stemming from use of small healthy volunteer cohorts from one or two countries for normative data. Further, significant technical limitations in analysis exist, such as inclusion of pH drops from meals/artefacts and inconsistent rules for identification of impedance reflux events, leading to large inter-reviewer variability. Several measurement systems are used for impedance-pH monitoring worldwide. Despite regional differences in prevalence of GERD phenotypes, symptomatic profiles and GERD complications, the same impedance-pH threshold values are used to define normality by these measurement systems. It remains unclear if measurements obtained using different systems or across world regions are comparable, especially since automated analysis provided by impedance-pH systems suffers from significant overcall of reflux episodes. Accurate identification and quantification of acid and non-acid reflux episodes on impedance-pH monitoring is important for precise calculation of oesophageal acid exposure time (AET), for reflux-symptom association analysis, and for evaluation of clearance mechanisms such as the postreflux swallow induced peristaltic wave (PSPW). Both reflux episodes and PSPW need to be reliably identified and recorded, for correct calculation of the PSPW index. Baseline impedance from impedance-pH monitoring can provide a measure of oesophageal mucosal integrity. Baseline impedance during the nocturnal supine period has been shown to be higher in healthy subjects and patients with functional heartburn and lower in patients with reflux disease. We aimed to obtain a new set of normal values for impedance- pH monitoring based on consensus analysis of impedance pH studies performed using different hardware/software systems from a large worldwide cohort of healthy asymptomatic subjects.
  2. RATIONALE Although normal values are available for commonly used impedance-pH parameters, their global application has limitations, stemming from use of small healthy volunteer cohorts from one or two countries for normative data. At present, there is no normative data for impedance-pH monitoring in Indian population. The aim of this study is to obtain a new set of normal values specific for the Indian population.
  3. STUDY OBJECTIVES 3a. Primary objective - To establish normative data for impedance-pH monitoring in Indian population.
  4. STUDY POPULATION- 50 healthy asymptomatic subjects
  5. DESIGN AND DURATION OF THE STUDY- It will be a observational prospective study. The study duration will be till completion of data collection for 50 subjects.

6a. SUBJECT RECRUITMENT - Healthy volunteers

6b. RANDOMIZATION AND BLINDING- Not applicable

6c. STUDY METHODS- This observational study will be conducted among 50 patients of both sexes after obtaining ethical clearance from institutional human ethical committee. Study participants will be of the age more than 18 years. Exclusion criteria will consist of thoracic or digestive foregut surgery, alcohol consumption >40 g/day, use of medications that alter intragastric acidity or oesophageal motility, as well as history of diabetes mellitus, neurological disorders or other chronic gastrointestinal disease.

6d. STUDY PROCEDURE- After at least 6 hours of fasting, a catheter will be placed through the nasal passage, and then swallowed into the esophagus with drinks of water. The other end of the catheter will be taped to cheek, wrapped over ear, and attached to a small data recorder that the subject will wear at waist level, held by a strap over the shoulder. Subject will be able to swallow, talk, and breathe without any difficulty during the test. Placement of the catheter will take about 10 minutes. One pH electrode will be positioned 5 cm proximal to the manometrically identified lower oesophageal sphincter (LES), and six impedance channels with their midpoint located 3, 5, 7, 9, 15 and 17 cm proximal to the LES. During the recording period, subjects will be encouraged to continue with their usual daily activities and meals. Subjects will be asked to keep a diary during the testing, including every time you eat, drink, or take medicines, and how long that lasts, when you lie down and get up, and each and every time you have a symptom of interest (like heartburn, regurgitation, cough, sore throat, etc.). Subject cannot take a shower or bath while wearing the monitor. Suject will return next day to have the catheter removed and to turn in the diary. Removing the catheter takes less than one minute. The total duration of catheter placement will be 24 hours. The equipment used will be pH monitoring catheter (Alacer, Brazil).

6e. METHODS OF ASSESSMENT- All tracings will be initially checked, and excluded if they had technical artefacts, marked oesophageal symptoms or antireflux medication intake. During the subsequent analysis process, tracings will be excluded if they fulfilled criteria for behavioural disorders (aerophagia, supragastric belching and rumination), low mean nocturnal baseline impedance (MNBI) in all impedance channels suspicious for eosinophilic oesophagitis (EoE) and hiatal hernia larger than 2 cm (in those with available HRM). All tracings will be analysed by four individuals, each with experience in reviewing >300 impedance-pH studies annually. Reviewers will initially apply automated analysis, followed by manual review of each identified reflux episode and PSPW for accuracy, as well as manual addition of missed events identified within the time window of 3 min used to edit the reflux events detected by automated analysis, with two reviewer consensus for each retained episode. The analysis process will consist of: (1) editing of pH drops (to exclude artefacts and meal/drink induced pH drops). Slow pH drifts without impedance reflux were included for calculation of total AET but were not considered separate reflux episodes. (2) Identification of impedance reflux events and PSPW using strict pre-established criteria and (3) measurement of distal MNBI. After manual editing, the following parameters will be considered for normative data: total, upright and supine AET, number of reflux events (total, acid and non-acid), PSPW index and MNBI at 3 and 5 cm above the LES.

6f. STOPPING OR DISCONTINUATION CRITERIA- Not applicable

  1. OUTCOME MEASURES 7a. Primary - To establish normative data for impedance-pH monitoring in Indian population.

There are no secondary objectives.

  1. STATISTICAL ANALYSIS- Data will be expressed as median and percentile values (5th, 25th, 75th and 95th percentiles). Depending on normality of distribution, we will use either paired Student's t-test or Mann-Whitney U test for paired comparison. Likewise, we will use one way analysis of variance with Tukey test or Kruskal-Wallis, followed by Dunn's test as appropriate. Upper limit of normal will be defined as the 95th percentile of normal values. For PSPW index and MNBI thresholds, we will use the 5th and 25th percentile values. P≤0.05 will be considered statistically significant.
Being tested
24 hour pH & impedance monitoring
Keywords
esophageal diseases, normative data, Reflux disease
Medical subject headings
Esophageal Diseases, Esophagitis, Gastroesophageal Reflux

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • 24 hour pH & impedance monitoringDiagnostic test

    24 hour pH impedance monitoring will be done on healthy subjects so that normative data specific to indian population can be generated.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Normative values for impedance-pH monitoring in healthy Indian population.

    There is no normative data for impedance-pH monitoring specific to indian population. The study aims to generate a reference value for the same by enrolling healthy individuals.

    Measured: six months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted13 Aug 2021
  2. Study start1 Jun 2021
  3. Primary completion31 Dec 2022 (estimated)
  4. Study completion31 Dec 2022 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
50 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05004155
Sponsor's protocol ID
AIG/IEC-BH&R 11/03 2021-01
Status last verified
Feb 2022
First submitted
4 Aug 2021
Last updated
3 Mar 2022
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No: There is no plan to share IPD.

Publications

  • Sifrim D, Roman S, Savarino E, Bor S, Bredenoord AJ, Castell D, Cicala M, de Bortoli N, Frazzoni M, Gonlachanvit S, Iwakiri K, Kawamura O, Krarup A, Lee YY, Soon Ngiu C, Ndebia E, Patcharatraku T, Pauwels A, Perez de la Serna J, Ramos R, Remes-Troche JM, Ribolsi M, Sammon A, Simren M, Tack J, Tutuian R, Valdovinos M, Xiao Y, Zerbib F, Gyawali CP. Normal values and regional differences in oesophageal impedance-pH metrics: a consensus analysis of impedance-pH studies from around the world. Gut. 2021 Jul 12;70(8):1441-1449. doi: 10.1136/gutjnl-2020-322627.

    PubMed 33037054
  • Roman S, Gyawali CP, Savarino E, Yadlapati R, Zerbib F, Wu J, Vela M, Tutuian R, Tatum R, Sifrim D, Keller J, Fox M, Pandolfino JE, Bredenoord AJ; GERD consensus group. Ambulatory reflux monitoring for diagnosis of gastro-esophageal reflux disease: Update of the Porto consensus and recommendations from an international consensus group. Neurogastroenterol Motil. 2017 Oct;29(10):1-15. doi: 10.1111/nmo.13067. Epub 2017 Mar 31.

    PubMed 28370768
  • Zerbib F, des Varannes SB, Roman S, Pouderoux P, Artigue F, Chaput U, Mion F, Caillol F, Verin E, Bommelaer G, Ducrotte P, Galmiche JP, Sifrim D. Normal values and day-to-day variability of 24-h ambulatory oesophageal impedance-pH monitoring in a Belgian-French cohort of healthy subjects. Aliment Pharmacol Ther. 2005 Nov 15;22(10):1011-21. doi: 10.1111/j.1365-2036.2005.02677.x.

    PubMed 16268977
  • Shay S, Tutuian R, Sifrim D, Vela M, Wise J, Balaji N, Zhang X, Adhami T, Murray J, Peters J, Castell D. Twenty-four hour ambulatory simultaneous impedance and pH monitoring: a multicenter report of normal values from 60 healthy volunteers. Am J Gastroenterol. 2004 Jun;99(6):1037-43. doi: 10.1111/j.1572-0241.2004.04172.x.

    PubMed 15180722

Questions about this trial

What is this clinical trial studying?

An observational study of Esophageal Diseases and Esophagitis, run by Asian Institute of Gastroenterology, India at 1 site in India.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 3 Mar 2022. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in India. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Anirrudha P Singh, MBBS, MD, DM (9004093248 ext. 91, draniruddhapratapsingh@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Normative values for impedance-pH monitoring in healthy Indian population. (time frame: six months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT05004155, which also lists 4 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Mar 2022; AzTrials last refreshed its copy on 27 Oct 2026.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in